Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial
Titel:
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial
Auteur:
Pitisuttithum, Punnee Luvira, Viravarn Lawpoolsri, Saranath Muangnoicharoen, Sant Kamolratanakul, Supitcha Sivakorn, Chaisith Narakorn, Piengthong Surichan, Somchaiya Prangpratanporn, Sumalee Puksuriwong, Suttida Lamola, Steven Mercer, Laina D. Raghunandan, Rama Sun, Weina Liu, Yonghong CarreƱo, Juan Manuel Scharf, Rami Phumratanaprapin, Weerapong Amanat, Fatima Gagnon, Luc Hsieh, Ching-Lin Kaweepornpoj, Ruangchai Khan, Sarwat Lal, Manjari McCroskery, Stephen McLellan, Jason Mena, Ignacio Meseck, Marcia Phonrat, Benjaluck Sabmee, Yupa Singchareon, Ratsamikorn Slamanig, Stefan Suthepakul, Nava Tcheou, Johnstone Thantamnu, Narumon Theerasurakarn, Sompone Tran, Steven Vilasmongkolchai, Thanakrit White, Jessica A Bhardwaj, Nina Garcia-Sastre, Adolfo Palese, Peter Krammer, Florian Poopipatpol, Kittisak Wirachwong, Ponthip Hjorth, Richard Innis, Bruce L